Literature DB >> 9420061

Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.

M A Visalli1, M R Jacobs, P C Appelbaum.   

Abstract

Activities of BAY 12-8039 against 205 pneumococci were tested by agar dilution. MICs (in micrograms per milliliter) at which 50 and 90% of the isolates are inhibited (MIC50s and MIC90s, respectively) were 0.125 and 0.25 (BAY 12-8039), 2.0 and 4.0 (ciprofloxacin and ofloxacin), and 0.25 and 0.5 (sparfloxacin). Beta-lactam MIC50s and MIC90s for penicillin-susceptible, -intermediate, and -resistant strains, in that order, were 0.016 and 0.03, 0.25 and 2.0, and 2.0 and 4.0 (amoxicillin); 0.03 and 0.06, 0.25 and 4.0, and 4.0 and 8.0 (ampicillin); 0.03 and 0.06, 0.5 and 4.0, and 4.0 and 8.0 (cefuroxime); and 0.03 and 0.125, 0.25 and 2.0, and 4.0 and 8.0 (cefpodoxime). At two times their MICs after 24 h, BAY 12-8039, ciprofloxacin, ampicillin, and cefuroxime were uniformly bactericidal (99.9% killing) against 12 strains; other compounds were bactericidal at four times their MICs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420061      PMCID: PMC164211     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

6.  In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

Authors:  E Wakabayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

Authors:  S K Spangler; M R Jacobs; G A Pankuch; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

8.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  In vitro activity of PD 127,391, an enhanced-spectrum quinolone.

Authors:  R Wise; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

10.  Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.

Authors:  L K McDougal; R Facklam; M Reeves; S Hunter; J M Swenson; B C Hill; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more
  11 in total

1.  Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Authors:  Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Comparative antipneumococcal activities of sulopenem and other drugs.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

3.  Penetration of moxifloxacin into peripheral compartments in humans.

Authors:  M Müller; H Stass; M Brunner; J G Möller; E Lackner; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

Authors:  D F Sahm; D E Peterson; I A Critchley; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

6.  Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; P C Yang; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.

Authors:  Shuyun Xu; Shengdao Xiong; Yongjian Xu; Jin Liu; Huiguo Liu; Jianping Zhao; Weining Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

8.  Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Lois M Ednie; Glenn Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.

Authors:  Frederick A Browne; Bülent Bozdogan; Catherine Clark; Linda M Kelly; Lois Ednie; Klaudia Kosowska; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.

Authors:  Catherine Clark; Kathy Smith; Lois Ednie; Tatiana Bogdanovich; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.